You are here

NDA for Anti-Insomnia Candidate Filed With FDA

MARLBOROUGH, Mass., April 2 /PRNewswire-FirstCall/-- Sepracor Inc. (Nasdaq: SEPR - News) today announced that the U.S. Food and Drug Administration (FDA) has filed Sepracor's New Drug Application (NDA) for ESTORRA(TM) brand eszopiclone 2 mg and 3 mg tablets for the treatment of transient and chronic insomnia. ESTORRA was studied in the 3 mg dosage strength for adults and in the 2 mg dosage strength for treatment of the elderly population. Sepracor submitted the ESTORRA NDA to the FDA on January 31, 2003.

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs